Michael Powell - 14 Jun 2023 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Director
Issuer ticker: GRTX
Reported as of: 14 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2023, 16:15:35 UTC
Prior SEC filing: 16 Jun 2022
Next SEC filing: 12 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Christopher Degnan, Attorney-in-Fact for Michael F. Powell

Key filing fact

Michael Powell filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 16 Jun 2023.

Key facts

This page summarizes Michael Powell's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2023, 16:15.

Change

Previous filing in this sequence was filed on 16 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +64,000
Change %
Price: $0.000000
Shares after: 64,000
Date: 14 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,000
Exercise price: $3.27
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.